Here are nine things to know from the report.
• Linaclotide in IBS-C. AGA recommends use (strong recommendation, high-quality evidence).
• Lubiprostone in IBS-C. AGA suggests use (conditional recommendation, moderate-quality evidence).
• PEG laxatives in IBS-C. AGA suggests use (conditional recommendation, low-quality evidence).
• Rifaximin in IBS-D. AGA suggests use (conditional recommendation, moderate-quality evidence).
• Alosetron in IBS-D. AGA suggests use (conditional recommendation, moderate-quality evidence).
• Loperamide in IBS-D. AGA suggests use (conditional recommendation, very low-quality evidence).
• Tricyclic antidepressants in IBS. AGA suggests use (conditional recommendation, low-quality evidence).
• Selective serotonin reuptake inhibitors in IBS. AGA suggests use (conditional recommendation, low-quality evidence).
• Antispasmodics in IBS. AGA suggests use (conditional recommendation, low-quality evidence).
More articles on gastroenterology:
7 professional GI society updates
Beyond proceduralism for practice improvement: 3 gastroenterologists’ best ideas
4 must-reads on Crohn’s disease
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.